Objectives of Study:
|
Gastric neuroendocrine tumors (g-nets) are a kind of rare tumors. According to SEER database, the incidence rate is 0.48/100000 people. In recent years, with the development of endoscopic technology, the detection rate has increased year by year, and the incidence rate of g-nets has increased 15 times. Among them, the most common type 1 g-nets have a low degree of malignancy. More than 95% of the patients are in the local early stage, with a median survival time of more than 10 years. The tumors are manifested as multiple and small polypoid lesions under endoscopy. Modern medical treatment is mainly endoscopic resection, and regular follow-up is required. If recurrence of tumors is found, they will be resected. However, the disease is recognized as a recurrent disease, with a recurrence rate of 63.6% and a short median recurrence time of about 8 months. Repeated resection under endoscopy alone will cause greater trauma and further aggravate the symptoms of patients' digestive tract. Therefore, seeking a treatment method with less damage to patients, better comprehensive treatment effect, non-invasive, safety, comfort and economy is the hotspot and difficulty in current clinical practice.
Compared with modern medicine, TCM diagnosis and treatment system has unique advantages. Professor Tan Huangying of China Japan Friendship Hospital summarized years of clinical experience and created "Shumu Liujunzi Decoction", which is effective in reducing the recurrence rate of type 1 G-Net patients, improving clinical symptoms and quality of life, and has been widely verified in basic and clinical research. In terms of treatment, multi center and two-way cohort studies have proved that combined Chinese medicine treatment can effectively reduce the recurrence rate of type 1 g-nets, prolong the median recurrence time, and slow down the clinical symptoms of patients than endoscopic resection alone. Based on the above research, we also explored the drug mechanism of traditional Chinese medicine to prevent the recurrence of type 1 g-nets, and found that the traditional Chinese medicine compound Shumu Liujunzi Decoction can promote the expression of DUSP1 target genes and thus reduce the high expression level of mirna-202-3p, thereby inhibiting the recurrence of type 1 g-nets. The treatment of type 1 g-nets with integrated Chinese and Western medicine has obvious advantages and is a better choice to break through the current treatment dilemma. However, the application of this formula in type 1 g-nets needs to be confirmed in clinical studies with larger samples.
Therefore, we plan to carry out a prospective, randomized, placebo-controlled clinical study to evaluate the impact of "Shumu Liujunzi Decoction" combined with western medicine endoscopic treatment, a combination strategy of Chinese and Western medicine, on the recurrence rate, recurrence time, quality of life of patients with type 1 g-nets, and on multidimensional clinical parameters such as endoscopic grading of atrophic gastritis and pathological grading of gastroscopic biopsy. Finally, the therapeutic effect of "Shumu Liujunzi Decoction" on type 1 g-nets was clarified, and the paradigm of Integrated Chinese and Western medicine was formulated to provide reliable evidence-based evidence for the formulation of guideline consensus, broaden the new path of type 1 g-nets treatment, and reduce the burden of disease.
|
Description for medicine or protocol of treatment in detail:
|
Experimental group: take Shumu Liujunzi Fang granules orally. From the 0 th month to the 12 th month, take it once with warm water after breakfast and dinner, and take 1 bag each time. About 84 subjects were randomly assigned to treatment group 1. Every five days, stop taking medicine for two days. Follow up treatment under western medicine endoscopy: from the 0th month to the 24th month, electronic gastroscopy is performed every 6 months. If there are lesions ≥ 5mm, endoscopic resection is performed.
Control group: take placebo granules orally. From the 0th month to the 12th month, take them once with warm water after breakfast and dinner, and take 1 bag each time. About 84 subjects were randomly assigned to treatment group 1. Every five days, stop taking medicine for two days. Follow up treatment under western medicine endoscopy: from the 0th month to the 24th month, electronic gastroscopy is performed every 6 months. If there are lesions ≥ 5mm, endoscopic resection is performed.
|
Inclusion criteria
|
(1)Age ≥ 18 years old
(2)According to the WHO (5th) classification and grading standards for gastrointestinal / hepatobiliary pancreatic neuroendocrine tumors in 2019, combined with the CSCO guidelines for diagnosis and treatment of neuroendocrine tumors (2021 Edition), type 1 g-nets were diagnosed: gastric neuroendocrine tumors (netg1 or netg2) with good differentiation were pathologically diagnosed. Serum gastrin was elevated, gastric parietal cell antibodies were positive, internal factor antibodies were positive, vitamin B12 was deficient, and gastroscopy showed multiple and polypoid lesions, Gastroscopy and pathology suggested (autoimmune) atrophic gastritis, HP (-), exclusion type 2 g-nets.
(3)Informed consent was signed.
|